BACKGROUND:Adenosine is a potent immunoregulatory nucleoside produced during inflammatory states to limit tissue damage. We hypothesized that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosine concentration and dampen chronic inflammation associated with human immunodeficiency virus (HIV) type 1. METHODS:Virally suppressed participants receiving antiretroviral therapy were randomized 1:1 for 12 weeks of dipyridamole (100 mg 4 times a day) versus placebo capsules. All participants took open-label dipyridamole during weeks 12-24. Study end points included changes in markers of systemic inflammation (soluble CD163 and CD14, and interleukin 6) and levels of T-cell immune activation (HLA-DR+CD38+). RESULTS: Of 40 participants who were randomized, 17 dipyridamole and 18 placebo recipients had baseline and week 12 data available for analyses. There were no significant changes in soluble markers, apart from a trend toward decreased levels of soluble CD163 levels (P = .09). There was a modest decrease in CD8+ T-cell activation (-17.53% change for dipyridamole vs +13.31% for placebo; P = .03), but the significance was lost in the pooled analyses (P = .058). Dipyridamole also reduced CD4+ T-cell activation (-11.11% change; P = .006) in the pooled analyses. In post hoc analysis, detectable plasma dipyridamole levels were associated with higher levels of inosine, an adenosine surrogate, and of cyclic adenosine monophosphate. CONCLUSION:Dipyridamole increased extracellular adenosine levels and decreased T-cell activation significantly among persons with HIV-1 infection receiving virally suppressive therapy.
RCT Entities:
BACKGROUND:Adenosine is a potent immunoregulatory nucleoside produced during inflammatory states to limit tissue damage. We hypothesized that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosine concentration and dampen chronic inflammation associated with human immunodeficiency virus (HIV) type 1. METHODS: Virally suppressed participants receiving antiretroviral therapy were randomized 1:1 for 12 weeks of dipyridamole (100 mg 4 times a day) versus placebo capsules. All participants took open-label dipyridamole during weeks 12-24. Study end points included changes in markers of systemic inflammation (soluble CD163 and CD14, and interleukin 6) and levels of T-cell immune activation (HLA-DR+CD38+). RESULTS: Of 40 participants who were randomized, 17 dipyridamole and 18 placebo recipients had baseline and week 12 data available for analyses. There were no significant changes in soluble markers, apart from a trend toward decreased levels of soluble CD163 levels (P = .09). There was a modest decrease in CD8+ T-cell activation (-17.53% change for dipyridamole vs +13.31% for placebo; P = .03), but the significance was lost in the pooled analyses (P = .058). Dipyridamole also reduced CD4+ T-cell activation (-11.11% change; P = .006) in the pooled analyses. In post hoc analysis, detectable plasma dipyridamole levels were associated with higher levels of inosine, an adenosine surrogate, and of cyclic adenosine monophosphate. CONCLUSION:Dipyridamole increased extracellular adenosine levels and decreased T-cell activation significantly among persons with HIV-1 infection receiving virally suppressive therapy.
Authors: Anthony R Cillo; David Vagratian; Margaret A Bedison; Elizabeth M Anderson; Mary F Kearney; Elizabeth Fyne; Dianna Koontz; John M Coffin; Michael Piatak; John W Mellors Journal: J Clin Microbiol Date: 2014-09-03 Impact factor: 5.948
Authors: Ilona Tóth; Anh Q Le; Philip Hartjen; Adriana Thomssen; Verena Matzat; Clara Lehmann; Christoph Scheurich; Claudia Beisel; Philipp Busch; Olaf Degen; Ansgar W Lohse; Thomas Eiermann; Gerd Fätkenheuer; Dirk Meyer-Olson; Maximilian Bockhorn; Joachim Hauber; Jan van Lunzen; Julian Schulze Zur Wiesch Journal: J Leukoc Biol Date: 2013-05-24 Impact factor: 4.962
Authors: Allan R Tenorio; Ellen S Chan; Ronald J Bosch; Bernard J C Macatangay; Sarah W Read; Suria Yesmin; Babafemi Taiwo; David M Margolis; Jeffrey M Jacobson; Alan L Landay; Cara C Wilson Journal: J Infect Dis Date: 2014-09-11 Impact factor: 5.226
Authors: Guillaume J Besson; Christina M Lalama; Ronald J Bosch; Rajesh T Gandhi; Margaret A Bedison; Evgenia Aga; Sharon A Riddler; Deborah K McMahon; Feiyu Hong; John W Mellors Journal: Clin Infect Dis Date: 2014-07-29 Impact factor: 9.079
Authors: Keri N Althoff; Kathleen A McGinnis; Christina M Wyatt; Matthew S Freiberg; Cynthia Gilbert; Krisann K Oursler; David Rimland; Maria C Rodriguez-Barradas; Robert Dubrow; Lesley S Park; Melissa Skanderson; Meredith S Shiels; Stephen J Gange; Kelly A Gebo; Amy C Justice Journal: Clin Infect Dis Date: 2014-10-30 Impact factor: 9.079
Authors: Christina Mallarino-Haeger; Kaleab Z Abebe; Edwin K Jackson; Ashley Zyhowski; Cynthia Klamar-Blain; Joshua C Cyktor; Diane Comer; Rhonda M Brand; Delbert G Gillespie; Kyle Holleran; John W Mellors; Ian McGowan; Sharon A Riddler; Bernard J C Macatangay Journal: J Acquir Immune Defic Syndr Date: 2020-12-15 Impact factor: 3.771
Authors: Boghuma Titanji; Christina Gavegnano; Priscilla Hsue; Raymond Schinazi; Vincent C Marconi Journal: J Am Heart Assoc Date: 2020-01-24 Impact factor: 5.501